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Abstract
Objectives—To ensure generalizability of clinical research results, it is important to enroll a 
heterogeneous population that is representative of the target clinical population. Earlier studies 
have found regional variation in participation in human immunodeficiency virus (HIV) clinical 
trials, with the lowest rates seen in the southern United States. Rates of new HIV diagnoses are 
highest in the South, highlighting the need for in-depth understanding of disparities in clinical trial 
participation. We evaluated whether regional variation in study participation remains, and describe 
factors that facilitate or prevent HIV clinical trial participation by region.
Methods—A one-time, anonymous, bilingual, self-administered survey was conducted among 
HIV-infected adults receiving HIV care at all 47 domestic AIDS Clinical Trials Group clinical 
research sites, with a goal of completing 50 surveys per site. χ2 tests were used to evaluate 
differences in knowledge of and participation in HIV clinical trials by region, including Northeast, 
Midwest, South, and West regions. Multivariable logistic regression was used to estimate odds 
ratios and 95% confidence intervals (CIs) for the effect of region on knowledge of and 
participation in HIV clinical trials.
Results—Of 2263 completed surveys, 2125 were included in this analysis. The proportion of 
respondents in the South who reported knowledge of studies (66%) was significantly lower than in 
the Northeast (76%), Midwest (77%), and West (73%) (P = 0.001). Respondents in the South also 
were the least likely group to report ever having tried to or having participated in a research study 
(51%) compared with respondents in the Northeast (60%), Midwest (57%), and West (69%; P < 
0.001). After adjusting for age, sex, education, race/ethnicity, tobacco use, and alcohol use, the 
OR for knowledge of and participation in clinical trials for the Northeast (1.36; 95% CI 1.07–1.72) 
and West (1.85; 95% CI 1.39–2.45) remained significant compared with the South. African 
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American respondents in the South were the most likely population group to report not 
understanding research studies (15%) as a reason for not participating, compared with the 
Northeast (9%), Midwest (8%), and West (6%; P < 0.001).
Conclusions—Significant regional variations in knowledge of and participation in HIV clinical 
trials exist. Our results suggest that increasing awareness and understanding of research studies, 
particularly among African Americans in the South, may facilitate HIV clinical trial participation 
that is more representative of the HIV-infected population across the United States.
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To ensure generalizability of clinical research results, it is important to enroll a 
heterogeneous population that is representative of the target clinical population. Women, 
racial/ethnic minorities, and those who have acquired the human immunodeficiency virus 
(HIV) by injection drug use are significantly underrepresented in HIV clinical trials in the 
United States.1–9 The HIV Cost and Service Utilization Study, a nationally representative 
sample of patients in care in the United States, using data from 1996 to 1998, found regional 
variation in the number of patients with HIV infection who had ever received experimental 
treatment, with the lowest participation noted in the South.4 Studies in the field of oncology 
also have revealed that the patients’ place of residence has been shown to have a statistically 
significant effect on accrual to oncology clinical trials, with southern states, including 
Alabama, Arkansas, Florida, Georgia, Kentucky, and West Virginia, having the lowest 
accrual rates.10
The 2011 Centers for Disease Control and Prevention’s HIV surveillance report shows 
regional variation in both the number of new HIV diagnoses and the total number of people 
living with HIV/acquired immunodeficiency syndrome (AIDS), with the highest rates of 
new HIV diagnoses now occurring in the South, followed by the Northeast, West, and 
Midwest in descending order.11 Prevalence of AIDS was highest in the Northeast, followed 
by the South, West, and Midwest. There are no recent studies that have extensively 
evaluated how enrollment in HIV clinical trials varies by region.
This article describes regional variation in knowledge of and participation in HIV clinical 
trials among a population of patients receiving care at AIDS Clinical Trials Group (ACTG) 
clinical research sites. We used an anonymous, bilingual, self-administered survey to assess 
potential barriers to HIV clinical trial enrollment. Differences in knowledge of available 
research studies and attitudes and beliefs that facilitate or prevent enrollment were compared 
across regions to better understand reasons why certain groups enroll less often. The results 
of this study will help demonstrate where to target additional programs to enhance HIV 
clinical trial participation.
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Survey Distribution and Content
The survey, developed by the Survey Working Group of the ACTG Underrepresented 
Populations Committee, was an anonymous, 7-page questionnaire written at a sixth-grade 
reading level, spanning 34 items in three categories: demographics, participation in clinical 
trials, and behaviors.
All 47 domestic ACTG clinical research sites were invited to participate in the survey and 
site participation was voluntary. All of the sites were sent 60 surveys in English and 12 in 
Spanish; however, the number of Spanish surveys could be increased upon site request. Sites 
were asked to distribute surveys, with a goal of completing 50 surveys per site. All ACTG 
sites participate in and offer patients access to clinical trials; however, patients cared for at 
these sites are not required to enroll in studies to receive routine HIV care at an ACTG site. 
HIV-infected individuals who were 18 years and older and attending the clinic site for 
regular medical care were approached for participation. Sites were encouraged to 
overrepresent women and minorities to allow for a diverse sample that would closely 
resemble the current demographics of the HIV epidemic in the United States. All of the sites 
obtained approval from their local institutional review board before initiating the study.
Respondents were given a paper copy of the survey and completed the survey confidentially. 
Respondents could receive assistance if they had problems reading the survey or if they had 
any questions regarding the survey. Once completed, the respondents placed the survey 
inside the provided envelope, sealed it, and gave it to the research nurse or coordinator. Sites 
were provided with preaddressed return shipping labels and were asked to return all 
completed surveys to the ACTG Data Management Center by completion of the enrollment 
period. Sites that did not adhere to this protocol were excluded from the analysis.
Statistical Analysis
χ2 tests of independence were used to evaluate differences in responses to the survey 
questions by region. No adjustments were made for multiple comparisons. Regions were 
defined according to geographic definitions set forth in the Centers for Disease Control and 
Prevention’s 2011 HIV surveillance report, as defined by the US Census Bureau11: 
Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, Kansas, 
Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and 
Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, 
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, 
Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, 
Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and 
Wyoming. Puerto Rico was not included in the analyses because it did not fit into one of the 
predefined geographic regions.
Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals 
(CIs) for the effect of region on participation in HIV clinical trials (outcome variable) 
defined as having ever tried to participate or having ever participated in HIV clinical trials. 
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Univariate models evaluated the association of participation with region, race, education, 
age, sex, last use of tobacco, alcohol use, and marijuana and other drug use. Only variables 
that were significant at a univariate level with a P ≤ 0.2 were included in the multivariable 
logistic regression model; sex was included in the multivariable model regardless of P value. 
All of the analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Demographics and Substance Abuse
A total of 3612 surveys were distributed to 47 sites and 2263 (63%) were returned. Five sites 
did not return any surveys. We included 2125 surveys in this analysis (88 were excluded 
from 2 sites because of protocol violations and 50 were excluded from the Puerto Rico site). 
The number of surveys completed by region was 682 (32%) from the Northeast, 498 (23%) 
from the Midwest, 516 (24%) from the South, and 429 (21%) from the West.
There were significant differences (P < 0.001) in age, race, sex, first language, and 
education levels in respondents among regions (Table 1). In the Midwest, more respondents 
were younger (younger than 34 years) and in the South, fewer respondents were older (older 
than 55 years). The survey was completed by fewer African Americans in the West (15%) 
and by fewer Hispanics in the Midwest (5%), as compared with other races and regions. The 
proportion of female respondents was highest in the Northeast (34%) and lowest in the West 
(15%). Only 2% reported Spanish as their first language in the Midwest, with other regions 
reporting 12% to 16%. Respondents in the West had higher overall levels of education, with 
13% reporting graduate-level education, and respondents in the Northeast had lower levels 
of education, with 50% reporting a high school education or less (Table 1).
Recent (in the past month) use of alcohol differed by region, with the highest proportions in 
the West and the West reporting the most daily or nearly daily alcohol drinkers. The 
Midwest had the highest percentage of recent tobacco users (47%). Marijuana use (in the 
past year) was highest in the West and Midwest. Cocaine/heroin/amphetamine use (in the 
past year) and use of injected drugs were highest in the West and Northeast (Table 1).
Knowledge of and Participation in Studies
Respondents in the South reported that they had less awareness of HIV research studies 
compared with other regions, with only 66% reporting knowledge of studies (pairwise P 
values for the South compared with the Northeast and Midwest <0.01, pairwise P values for 
the South compared with the West = 0.1) and 60% having ever been talked to about research 
studies (all pairwise P values for the South <0.01). Respondents in the South also were the 
least likely group to have ever thought about participating in a study (pairwise P values for 
the South compared with the Midwest and West <0.05, pairwise P values for the South 
compared with the Northeast = 0.2) and the least likely to have ever tried to participate in 
and to have ever participated in a research study (all pairwise P values for the South ≤0.05; 
Table 2).
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When asked why one would want to participate in a study, more respondents in the 
Northeast reported wanting better representation of their sex in research studies (28%) 
compared with the West and the Midwest (both 22%) and the South (25%, P=0.03). 
Respondents in the Northeast (29%) and the South (28%) reported wanting better 
representation of their race in research studies compared with the Midwest or West (both 
22%; P <0.006). Respondents in the West (43%) were more likely to report that they would 
want to participate in a research study if their healthcare provider recommended it (Table 2).
When asked why one would not want to participate in a study, respondents in the Midwest 
(19%) and West (22%) expressed more concern about receiving a placebo compared with 
the Northeast (13%) and South (14%); in the Midwest (23%) and South (20%), they 
expressed concern that their information would not be kept secret. Respondents in the South 
(11%) were most likely to report that they did not understand research studies compared 
with the Northeast (8%), Midwest (7%) and the West (5%, P=0.01; Table 2).
Sex by Region
We included 2070 surveys in the analysis of sex by region (Table 3). Respondents who 
reported being transgender (n = 13) or did not report sex (n = 44) were not included in the 
analysis. When asked why one would want to participate in a study, 34% of females in the 
South and 38% of female respondents in the West reported that they wanted more of their 
race represented in studies compared with 30% in the Northeast and 20% in the Midwest. 
Furthermore, 34% of female respondents in the South and 52% of female respondents in the 
West reported they wanted more of their sex represented in studies compared with 29% in 
the Northeast and 23% in the Midwest. When asked why one would not want to participate 
in a study, across all regions male respondents were more worried about receiving a placebo 
than female respondents. Furthermore, male respondents in the Midwest (22%) and in the 
West (25%) were more worried about placebo than male participants in the Northeast (14%) 
or South (15%; Table 3).
Race by Region
We included 1947 surveys in this analysis stratified by race and region, because respondents 
who reported other (n = 99), mixed race (n = 23), or did not report race (n = 56) were not 
included in the analysis (Table 4). More Hispanics (21%) in the Midwest reported they 
would not want to participate in a study because studies are not “friendly” to people of their 
race compared with the Northeast (9%, P = 0.06), South (8%, P = 0.08), and West (10%, P 
= 0.1). Hispanics in the Midwest (38%) also were more worried that their information would 
be revealed compared with Hispanics in the Northeast (11%, P = 0.001), South (23%, P = 
0.2), and West (20%, P = 0.06). Of note, the sample of Hispanics in the Midwest was small 
(n = 24). In the South, more African Americans (15%) reported they would not want to 
participate in a study because they do not understand studies as compared with 9%, 8%, and 
6% in the Northeast, Midwest, and West, respectively (Table 4). The education of African 
Americans was not lower per se in the South, because 56% of African Americans in the 
Northeast, 42% in the Midwest, 47% in the South, and 29% in the West reported having a 
high school education or less. African Americans were more likely than Hispanics to report 
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that they wanted more of their race to be included in research studies in all regions except 
the South, where the high rates were comparable (Table 4).
First Language by Region
We included 1992 surveys in this analysis because respondents who did not report a first 
language (n = 102) or who reported speaking other languages (n = 31) were not included in 
the analysis. Respondents who reported Spanish as a first language in the South were more 
likely to want to participate in a study because a provider recommended (51%) it compared 
with 35% in the Northeast (P = 0.04), and 36% in the West (P = 0.09). Spanish speakers in 
the South also reported that they would not want to participate in studies because they 
worried about receiving a placebo (22%) compared with 7% in the Northeast (P = 0.005), 
and 17% in the West (P = 0.5; Table 5). In all regions except the South, more respondents 
who reported Spanish as a first language, as compared with those who reported English as a 
first language, said they would not want to participate in a study because they do not 
understand studies. In the South, nearly equal percentages of respondents who reported 
English (12%) and Spanish (11%) as a first language would not want to participate in a 
study because they do not understand studies (Table 5).
Effect of Region on Participation in HIV Clinical Trials
Fifty-nine percent of the respondents reported that they had tried to participate in or had 
participated in an HIV/AIDS research study (Table 2). After adjusting for age, sex, 
education, race/ethnicity, tobacco use, and alcohol use, the OR for ever having tried to 
participate in or ever having participated in an HIV/AIDS research study remained 
significantly higher for respondents in the Northeast (1.36; 95% CI 1.07–1.72) and West 
(1.85; 95% CI 1.39–2.45) compared with the South (Table 6); the OR for the Midwest 
compared to the South was no longer statistically significant (P = 0.2; Table 6).
We also evaluated the combined effect of sex and race in a multivariate model that included 
region, age, education, tobacco use, and alcohol use. Compared with white males, African 
American males and Hispanic males were less likely to report having tried to participate or 
having participated in a study with adjusted ORs of 0.74 (95% CI 0.57–0.95) and 0.59 (95% 
CI 0.43–0.81), respectively. The associations for white, African American, or Hispanic 
females were not statistically significant. The associations of region with having tried to 
participate or having participated in a study in this model with the combined effect of sex 
and race were consistent with those reported in Table 6.
Discussion
In this study, we demonstrated that there was regional variation in knowledge of and 
participation in HIV clinical trials among HIV-infected patients cared for at clinical sites 
where HIV clinical trials were being conducted. Our results show that respondents in the 
South were less likely to have ever tried to participate in a study, ever talked with a provider 
about participating in a study or participated in a study, and they had the least knowledge 
about studies. We also found that more respondents in the South reported that they would 
not want to participate in a study because they did not understand research studies, despite 
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reporting more than high school education levels that were similar to other regions, except 
the West, where a higher proportion had post-college educations. Respondents in the South, 
which had the highest proportion of African American respondents, were more likely to 
want to participate in HIV trials because they believed that more people of their race should 
be represented in research studies. After adjusting for age, sex, education, race/ethnicity, 
tobacco use, and alcohol use, there was no longer a statistically significant difference 
between the South and the Midwest in respondents reporting having tried to participate in or 
having ever participated in an HIV/AIDS research study.
Authors have described the similarities in the HIV epidemic among states in the Deep South 
and less wealthy nations in comparison with other areas of the United States, and have 
postulated contributing factors such as a high prevalence of poverty, reliance on public 
health programs, and residence in rural areas.12 Studies investigating participation in cancer-
related trials have found that racial and ethnic minorities, older adults, rural residents, and 
individuals of low socioeconomic status are underrepresented in trials, with the most 
reported barrier to participation being lack of awareness of clinical trials.13
We also found that African Americans in the South were more likely to report they would 
not want to participate in a study because they do not understand studies compared with 
African Americans in the other regions of the country. Parallel to this finding, nearly equal 
percentages of English and Spanish speakers in the South stated that they would not want to 
participate in a study because they do not understand HIV studies, which differed from the 
other regions in which only Spanish speakers were more likely to report not understanding 
studies as a barrier to participation.
A study investigating the attitudes and beliefs of African Americans toward participation in 
medical research found African Americans were concerned that they would be the least 
likely group to benefit from research.14 In addition, the analogy of “being used as a guinea 
pig” was not only extended to research but also included perceptions of care in a teaching 
medical facility.14 In a cross-sectional survey of African Americans in Durham, North 
Carolina and their willingness to participate in AIDS research in 1998, Sengupta et al found 
that distrust of research institutions was the strongest barrier to participation in AIDS 
clinical trials.15
We found that African Americans across the United States reported not wanting to be “used 
as a guinea pig” as a reason to not participate in studies. This finding also is supported by a 
smaller-scale study that showed that geographic region, sex, and socioeconomic status had 
no perceivable influence on respondent knowledge or feelings toward medical research or 
the Tuskegee Syphilis Study in particular.16,17 Multiple studies have found that provider 
beliefs about patients influence their behavior with patients, and medical providers who care 
for HIV-infected patients have reported that they assume that people of color are less 
interested in clinical trials, less likely to join trials, and are therefore less likely to refer 
them.18–20
Our study had limitations. Our data were obtained from self-administered surveys, 
increasing the risk for reporting bias. Furthermore, the survey was distributed only to HIV-
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infected patients at sites where clinical trials are being conducted and these sites were asked 
to overrepresent women and minorities. The surveys were not distributed randomly, so the 
differences in demographic characteristics do not represent the population characteristics of 
these regions as a whole. Although our sample may not have been representative of the 
general population of HIV-infected individuals receiving medical care, our respondents were 
cared for at sites where clinical trials are conducted and should theoretically be more likely 
to have knowledge of clinical trials. We still found significant discrepancies in knowledge 
and participation in HIV clinical trials across regions, however.
Comprehensive enrollment of a heterogeneous population in HIV/AIDS trials, including 
patients from various racial, social, and geographic backgrounds, is essential to ensure that 
the results can be applied and generalized to HIV-infected patients receiving care in the 
United States. The results of our study demonstrated regional variations in knowledge of and 
participation in HIV clinical trials and this information can be used to develop programs to 
educate patients and clinicians and to enhance clinical trial participation. Our results suggest 
that increasing awareness and understanding of research studies, particularly in the South 
among African Americans, may facilitate HIV clinical trial participation across the United 
States.
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• Patients in the southern United States infected with the human 
immunodeficiency virus were the least likely group to have ever tried to 
participate in or to have ever participated in a research study, ever talked with a 
provider about participating in a study, or have knowledge about ongoing 
studies.
• More respondents in the South reported that they would not want to participate 
in a study because they did not understand research studies, despite reporting 
education levels similar to other regions.
• African Americans in the South were more likely to report they would not want 
to participate in a study because they do not understand studies compared with 
African Americans in the other regions of the country.
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Table 6
Odds ratios and 95% confidence intervals for the association of region with participation in HIV/AIDS 
research studies
Have you ever tried to participate in or have you ever participated in an 
HIV/AIDS research study?a
Unadjusted Adjusted
OR (95% CI) P OR (95% CI) P
Region
 South Ref Ref
 Northeast 1.43 (1.13–1.79) 0.003 1.36 (1.07–1.72) 0.01
 Midwest 1.28 (0.99–1.63) 0.05 1.18 (0.91–1.52) 0.2
 West 2.11 (1.62–2.75) <0.0001 1.85 (1.39–2.45) <0.0001
Race
 White Ref Ref
 African American 0.56 (0.45–0.69) <0.0001 0.68 (0.54–0.85) 0.001
 Hispanic 0.56 (0.43–0.72) <0.0001 0.63 (0.47–0.83) 0.001
Education
 High school or less Ref Ref
 More than high school 1.45 (1.22–1.74) <0.0001 1.27 (1.04–1.55) 0.02
Age categories, y
 <25 Ref Ref
 25–34 1.48 (0.89–2.45) 0.1 1.42 (0.85–2.39) 0.2
 35–44 1.68 (1.03–2.72) 0.04 1.62 (0.99–2.66) 0.06
 45–54 2.09 (1.30–3.37) 0.002 1.99 (1.22–3.25) 0.006
 ≥55 2.71 (1.63–4.48) 0.0001 2.39 (1.43–4.02) 0.001
Sex
 Male Ref Ref
 Female 1.11 (0.91–1.35) 0.3 1.30 (1.05–1.61) 0.01
Last use of tobacco
 Never/>1 y ago Ref Ref
 Within past year or past month 0.86 (0.72–1.04) 0.1 0.93 (0.77–1.13) 0.5
Alcohol use
 Never or 1/mo Ref Ref
 >2–3 times/mo 1.11 (0.93–1.34) 0.2 1.14 (0.95–1.39) 0.2
Marijuana use
 Never/>1 y ago Ref —
 Within past month/year 1.12 (0.92–1.38) 0.3 — —
Other drug use (cocaine, heroin, amphetamine)
 Never/>1 y ago Ref —
 Within past month/year 1.08 (0.83–1.42) 0.6 — —
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Based on the univariate analyses, variables with P ≤ 0.2 were included in the adjusted model; sex was included in the model regardless of P value. 
Mixed race, transgender, and missing responses not shown in table (all P > 0.05). AIDS, acquired immunodeficiency syndrome; CI, confidence 
interval; HIV, human immunodeficiency virus; OR, odds ratio.
a
Yes 1245, no 880. Odds ratios are for yes vs no.
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